Objectives To investigate the concentration of plasma plasminogen activator inhibitor-1 and the promoter-844G-A substitution,-675 4G/5G polymorphism in patients with CHD and control.
Methods 293 patients with CHD (UAP group andAMIgroup)and 173 human in health (control group )were studied. Plasma PAI-1 antigen was measured by ELISA. The segment of PAI-1 gene was amplified by PCR(-675 4G/5G and-844 G-A). The products of PCR were digested by Xho I(-844 G-A)
Results No difference in genotype frequency was observed in both groups in-844 G-A. There is a difference in genotype frequency was observed between AMI group and the control group in-675 4G/5G, But no difference between UAP and the control in-675 4G/5G. Plasma level of PAI-1 antigen both in UAP and AMI group was higher than that in control group (43.2 ± 22.71 ng/ml, 62.2 ± 24.52 ng/ml, 31.8 ± 25.12 ng/ml, p < 0.01) and related to the 4G/5G and G-A Polymorphism. Carriers of 4G allele have high plasma PAI-1 antigen level.
Conclusions PAI-1 plays an important role in regulation of the fibrinolysis function. In patients with UAP or AMI the PAI-1 antigen was much higher. Promoter-844 G∼A substitution polymorphism have no relationship with the occurrence of UAP and AMI, but-675 4G/5G polymorphism have a relationship with the occurrence of AMI. Carriers of 4G allele have high plasma PAI-1 antigen level.